[{"address1": "2625 Townsgate Road", "address2": "Suite 230", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 267 9889", "website": "https://www.genelux.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 24, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Zindrick J.D.", "age": 64, "title": "Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 570990, "exercisedValue": 0, "unexercisedValue": 11528577}, {"maxAge": 1, "name": "Ms. Lourie S. Zak", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 346195, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Jewett", "age": 58, "title": "VP & Head of Quality", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 269264, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph  Cappello Ph.D.", "age": 66, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 213077, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  Ryder J.D.", "age": 54, "title": "General Counsel & Corporate Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 380000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yong  Yu Ph.D.", "age": 52, "title": "Senior Vice President of Clinical Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 242615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Paul  Scigalla M.D., Ph.D.", "age": 78, "title": "Chief Medical Officer", "yearBorn": 1945, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ralph  Smalling B.Sc.", "age": 66, "title": "VP & Head of Regulatory Affairs", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1724803200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.98, "open": 2.04, "dayLow": 2.04, "dayHigh": 2.3258, "regularMarketPreviousClose": 1.98, "regularMarketOpen": 2.04, "regularMarketDayLow": 2.04, "regularMarketDayHigh": 2.3258, "forwardPE": -2.3586957, "volume": 387669, "regularMarketVolume": 387669, "averageVolume": 202850, "averageVolume10days": 168520, "averageDailyVolume10Day": 168520, "bid": 2.11, "ask": 2.2, "bidSize": 100, "askSize": 100, "marketCap": 74942040, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 30.44, "priceToSalesTrailing12Months": 9367.755, "fiftyDayAverage": 2.1142, "twoHundredDayAverage": 6.358925, "currency": "USD", "enterpriseValue": 42572640, "floatShares": 27514969, "sharesOutstanding": 34535500, "sharesShort": 1238782, "sharesShortPriorMonth": 1346768, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0359, "heldPercentInsiders": 0.17848, "heldPercentInstitutions": 0.20577998, "shortRatio": 11.68, "shortPercentOfFloat": 0.0425, "bookValue": 1.105, "priceToBook": 1.9638009, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -26538000, "trailingEps": -0.95, "forwardEps": -0.92, "enterpriseToRevenue": 5321.58, "enterpriseToEbitda": -1.579, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNLX", "underlyingSymbol": "GNLX", "shortName": "Genelux Corporation", "longName": "Genelux Corporation", "firstTradeDateEpochUtc": 1674743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "818a2610-5027-31af-b56b-57304f2478db", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.17, "targetHighPrice": 32.0, "targetLowPrice": 10.0, "targetMeanPrice": 19.2, "targetMedianPrice": 19.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 33636000, "totalCashPerShare": 0.986, "ebitda": -26965000, "totalDebt": 2207000, "quickRatio": 5.796, "currentRatio": 6.009, "totalRevenue": 8000, "debtToEquity": 5.859, "returnOnAssets": -0.44608003, "returnOnEquity": -0.88571, "freeCashflow": -11902625, "operatingCashflow": -21445000, "grossMargins": 1.0, "operatingMargins": -3414.375, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-01"}]